Kura Oncology (KURA) Projected to Post Earnings on Wednesday

Kura Oncology (NASDAQ:KURA) is projected to post its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Kura Oncology to post earnings of ($0.65) per share and revenue of $57.96 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Kura Oncology Trading Up 1.2 %

Shares of KURA opened at $8.25 on Monday. The stock has a 50-day moving average price of $8.30 and a 200 day moving average price of $14.12. Kura Oncology has a one year low of $6.98 and a one year high of $24.17. The company has a market capitalization of $641.21 million, a P/E ratio of -3.49 and a beta of 0.78. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Insider Transactions at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock valued at $92,307 in the last three months. 5.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on KURA shares. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Bank of America lowered their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd. JMP Securities restated a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a research report on Thursday, February 6th. Finally, Wedbush raised their target price on Kura Oncology from $34.00 to $36.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $27.13.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.